| Year |
Citation |
Score |
| 2023 |
Schönauer R, Sierks D, Boerrigter M, Jawaid T, Caroff L, Audrezet MP, Friedrich A, Shaw M, Degenhardt J, Forberger M, de Fallois J, Bläker H, Bergmann C, Gödiker J, Schindler P, ... ... Drenth JPH, et al. Sex, genotype, and liver volume progression as risk of hospitalization determinants in autosomal dominant polycystic liver disease. Gastroenterology. PMID 38101549 DOI: 10.1053/j.gastro.2023.12.007 |
0.35 |
|
| 2023 |
Boerrigter MM, Duijzer R, Te Morsche RHM, Drenth JPH. Heterozygosity of ALG9 in Association with Autosomal Dominant Polycystic Liver Disease. Genes. 14. PMID 37761895 DOI: 10.3390/genes14091755 |
0.365 |
|
| 2023 |
Barten TRM, Atsma F, van der Meer AJ, Gansevoort R, Nevens F, Drenth JPH, Gevers TJG. Higher need for polycystic liver disease therapy in female patients: sex-specific association between liver volume and need for therapy. Hepatology (Baltimore, Md.). PMID 37725713 DOI: 10.1097/HEP.0000000000000602 |
0.315 |
|
| 2023 |
Waddell SH, Yao Y, Olaizola P, Walker A, Jarman EJ, Gournopanos K, Gradinaru A, Christodoulou E, Gautier P, Boerrigter MM, Cadamuro M, Fabris L, Drenth JP, Kendall TJ, Banales JM, et al. A TGFβ-ECM-integrin signaling axis drives structural reconfiguration of the bile duct to promote polycystic liver disease. Science Translational Medicine. 15: eabq5930. PMID 37703354 DOI: 10.1126/scitranslmed.abq5930 |
0.35 |
|
| 2023 |
Boerrigter MM, Te Morsche RHM, Venselaar H, Pastoors N, Geerts AM, Hoorens A, Drenth JPH. Novel α-1,3-Glucosyltransferase Variants and Their Broad Clinical Polycystic Liver Disease Spectrum. Genes. 14. PMID 37628703 DOI: 10.3390/genes14081652 |
0.347 |
|
| 2023 |
Zachou K, Azariadis K, Lytvyak E, Snijders RJALM, Takahashi A, Gatselis NK, Robles M, Andrade RJ, Schramm C, Lohse AW, Tanaka A, Drenth JPH, Montano-Loza AJ, Dalekos GN. Treatment responses and outcomes in patients with autoimmune hepatitis and concomitant features of non-alcoholic fatty liver disease. Jhep Reports : Innovation in Hepatology. 5: 100778. PMID 37456672 DOI: 10.1016/j.jhepr.2023.100778 |
0.333 |
|
| 2022 |
Olaizola P, Rodrigues PM, Caballero-Camino FJ, Izquierdo-Sanchez L, Aspichueta P, Bujanda L, Larusso NF, Drenth JPH, Perugorria MJ, Banales JM. Genetics, pathobiology and therapeutic opportunities of polycystic liver disease. Nature Reviews. Gastroenterology & Hepatology. PMID 35562534 DOI: 10.1038/s41575-022-00617-7 |
0.349 |
|
| 2022 |
van Son KC, Tushuizen ME, Holleboom AG, Drenth JPH. A non-invasive score for nonalcoholic fatty liver disease (NAFLD) cirrhosis. European Journal of Internal Medicine. 98: 43-44. PMID 35249779 DOI: 10.1016/j.ejim.2022.02.025 |
0.306 |
|
| 2021 |
Larsen LE, van den Boogert MAW, Rios-Ocampo WA, Jansen JC, Conlon D, Chong PLE, Levels JHM, Eilers RE, Sachdev VV, Zelcer N, Raabe T, He M, Hand NJ, Drenth JPH, Rader DJ, et al. Defective lipid droplet - lysosome interaction causes fatty liver disease as evidenced by human mutations in TMEM199 and CCDC115. Cellular and Molecular Gastroenterology and Hepatology. PMID 34626841 DOI: 10.1016/j.jcmgh.2021.09.013 |
0.32 |
|
| 2021 |
Aapkes SE, Bernts LHP, van den Berg M, Gansevoort RT, Drenth JPH. Tamoxifen for the treatment of polycystic liver disease: A case report. Medicine. 100: e26797. PMID 34397882 DOI: 10.1097/MD.0000000000026797 |
0.352 |
|
| 2021 |
Lee-Law PY, Olaizola P, Caballero-Camino FJ, Izquierdo-Sanchez L, Rodrigues PM, Perugorria MJ, Azkargorta M, Elortza F, Martinez-Chantar ML, Aspichueta P, Marzioni M, Bujanda L, Drenth JPH, Banales JM. Inhibition of NAE-dependent protein hyper-NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease. United European Gastroenterology Journal. PMID 34310849 DOI: 10.1002/ueg2.12126 |
0.327 |
|
| 2020 |
Hamid S, Alvares da Silva MR, Burak KW, Chen T, Drenth JPH, Esmat G, Gaspar R, LaBrecque D, Lee A, Macedo G, McMahon B, Ning Q, Reau N, Sonderup M, van Leeuwen DJ, et al. WGO Guidance for the Care of Patients With COVID-19 and Liver Disease. Journal of Clinical Gastroenterology. PMID 33230011 DOI: 10.1097/MCG.0000000000001459 |
0.366 |
|
| 2020 |
van de Laarschot LFM, Te Morsche RHM, Hoischen A, Venselaar H, Roelofs HM, Cnossen WR, Banales JM, Roepman R, Drenth JPH. Novel GANAB variants associated with polycystic liver disease. Orphanet Journal of Rare Diseases. 15: 302. PMID 33097077 DOI: 10.1186/s13023-020-01585-4 |
0.376 |
|
| 2020 |
Jansen JC, van Hoek B, Metselaar HJ, van den Berg AP, Zijlstra F, Huijben K, van Scherpenzeel M, Drenth JPH, Lefeber DJ. Screening for abnormal glycosylation in a cohort of adult liver disease patients. Journal of Inherited Metabolic Disease. PMID 32557671 DOI: 10.1002/jimd.12273 |
0.357 |
|
| 2020 |
Bernts LHP, Neijenhuis MK, Edwards ME, Sloan JA, Fischer J, Smoot RL, Nagorney DM, Drenth JPH, Hogan MC. Symptom relief and quality of life after combined partial hepatectomy and cyst fenestration in highly symptomatic polycystic liver disease. Surgery. PMID 32402542 DOI: 10.1016/j.surg.2020.02.014 |
0.306 |
|
| 2020 |
Santos-Laso A, Izquierdo-Sanchez L, Rodrigues PM, Huang BQ, Azkargorta M, Lapitz A, Munoz-Garrido P, Arbelaiz A, Caballero-Camino FJ, Fernández-Barrena MG, Jimenez-Agüero R, Argemi J, Aragon T, Elortza F, Marzioni M, ... Drenth JPH, et al. Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets. Liver International : Official Journal of the International Association For the Study of the Liver. PMID 32378324 DOI: 10.1111/liv.14485 |
0.304 |
|
| 2019 |
Groen MT, Drenth JPH, Voermans N. [Elevated liver enzyme levels; not exclusive to liver disease]. Nederlands Tijdschrift Voor Geneeskunde. 163. PMID 32073783 |
0.342 |
|
| 2019 |
Bernts LHP, Drenth JPH, Tjwa ETTL. Management of Portal Hypertension and Ascites in Polycystic Liver Disease. Liver International : Official Journal of the International Association For the Study of the Liver. PMID 31505092 DOI: 10.1111/liv.14245 |
0.322 |
|
| 2019 |
Bernts LHP, Jones DEJ, Kaatee MM, Lohse AW, Schramm C, Sturm E, Drenth JPH. Position statement on access to care in rare liver diseases: advancements of the European reference network (ERN) RARE-LIVER. Orphanet Journal of Rare Diseases. 14: 169. PMID 31287000 DOI: 10.1186/s13023-019-1152-z |
0.333 |
|
| 2019 |
van Aerts RMM, Kievit W, D'Agnolo HMA, Blijdorp CJ, Casteleijn NF, Dekker SEI, de Fijter JW, van Gastel M, Gevers TJ, van de Laarschot LFM, Lantinga MA, Losekoot M, Meijer E, Messchendorp AL, Neijenhuis MK, ... ... Drenth JPH, et al. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease. Gastroenterology. PMID 31022403 DOI: 10.1053/j.gastro.2019.04.018 |
0.345 |
|
| 2019 |
Bernts LHP, Tjwa ETTL, D'Agnolo HMA, Jenniskens SFM, Drenth JPH. Venous Stent Placement for Refractory Ascites due to Hepatic Venous Outflow Obstruction in Polycystic Liver Disease: A Case Report. Journal of Vascular and Interventional Radiology : Jvir. PMID 31005489 DOI: 10.1016/j.jvir.2018.09.011 |
0.301 |
|
| 2019 |
Lee-Law PY, van de Laarschot LFM, Banales JM, Drenth JPH. Genetics of polycystic liver diseases. Current Opinion in Gastroenterology. PMID 30652979 DOI: 10.1097/MOG.0000000000000514 |
0.3 |
|
| 2018 |
Munsterman ID, Duijnhouwer AL, Kendall TJ, Bronkhorst CM, Ronot M, van Wettere M, van Dijk APJ, Drenth JPH, Tjwa ETTL. The clinical spectrum of Fontan-associated liver disease: results from a prospective multimodality screening cohort. European Heart Journal. PMID 30346512 DOI: 10.1093/eurheartj/ehy620 |
0.326 |
|
| 2018 |
van Aerts RMM, Kolkman M, Kievit W, Gevers TJG, Nevens F, Drenth JPH. Drug holiday in patients with polycystic liver disease treated with somatostatin analogues. Therapeutic Advances in Gastroenterology. 11: 1756284818804784. PMID 30302127 DOI: 10.1177/1756284818804784 |
0.328 |
|
| 2018 |
van Aerts RMM, Kievit W, de Jong ME, Ahn C, Bañales JM, Reiterová J, Reiterová F, Drenth JPH. Severity in polycystic liver disease is associated with etiology and female gender; results of the International PLD Registry. Liver International : Official Journal of the International Association For the Study of the Liver. PMID 30225933 DOI: 10.1111/liv.13965 |
0.356 |
|
| 2018 |
Neijenhuis MK, Kievit W, Verheesen SM, D'Agnolo HM, Gevers TJ, Drenth JP. Impact of liver volume on polycystic liver disease-related symptoms and quality of life. United European Gastroenterology Journal. 6: 81-88. PMID 29435317 DOI: 10.1177/2050640617705577 |
0.311 |
|
| 2018 |
Weersink RA, Bouma M, Burger DM, Drenth JPH, Harkes-Idzinga SF, Hunfeld NGM, Metselaar HJ, Monster-Simons MH, Taxis K, Borgsteede SD. Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis. Drug Safety. PMID 29330714 DOI: 10.1007/s40264-017-0635-x |
0.311 |
|
| 2016 |
D'Agnolo HM, Kievit W, Takkenberg RB, Riaño I, Bujanda L, Neijenhuis MK, Brunenberg EJ, Beuers U, Banales JM, Drenth JP. Ursodeoxycholic acid in advanced polycystic liver disease: an international multicenter randomized controlled phase 2 trial: CURSOR: Controlled trial of URSOdeoxycholic acid to Reduce liver volume in polycystic liver disease. Journal of Hepatology. PMID 27212247 DOI: 10.1016/j.jhep.2016.05.009 |
0.329 |
|
| 2015 |
Gevers TJ, Nevens F, Torres VE, Hogan MC, Drenth JP. Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis. Liver International : Official Journal of the International Association For the Study of the Liver. PMID 26481454 DOI: 10.1111/liv.12986 |
0.337 |
|
| 2015 |
Cnossen WR, Maurits JS, Salomon J, Te Morsche RH, Waanders E, Drenth JP. Severe Polycystic Liver Disease Is Not Caused by Large Deletions of the PRKCSH Gene. Journal of Clinical Laboratory Analysis. PMID 26365003 DOI: 10.1002/jcla.21875 |
0.343 |
|
| 2015 |
Cnossen WR, Te Morsche RH, Hoischen A, Gilissen C, Venselaar H, Mehdi S, Bergmann C, Losekoot M, Breuning MH, Peters DJ, Veltman JA, Drenth JP. LRP5 variants may contribute to ADPKD. European Journal of Human Genetics : Ejhg. PMID 25920554 DOI: 10.1038/ejhg.2015.86 |
0.314 |
|
| 2015 |
Drenth JP, Montagnese S. First evidence-based guidelines for the diagnosis and management of hepatic encephalopathy: A welcome development. Journal of Hepatology. 62: 1457. PMID 25911334 DOI: 10.1016/J.Jhep.2015.02.033 |
0.348 |
|
| 2015 |
Gevers TJ, Hol JC, Monshouwer R, Dekker HM, Wetzels JF, Drenth JP. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial. Liver International : Official Journal of the International Association For the Study of the Liver. 35: 1607-14. PMID 25369108 DOI: 10.1111/liv.12726 |
0.323 |
|
| 2014 |
Cnossen WR, Drenth JP. Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management. Orphanet Journal of Rare Diseases. 9: 69. PMID 24886261 DOI: 10.1186/1750-1172-9-69 |
0.373 |
|
| 2014 |
Cnossen WR, te Morsche RH, Hoischen A, Gilissen C, Chrispijn M, Venselaar H, Mehdi S, Bergmann C, Veltman JA, Drenth JP. Whole-exome sequencing reveals LRP5 mutations and canonical Wnt signaling associated with hepatic cystogenesis. Proceedings of the National Academy of Sciences of the United States of America. 111: 5343-8. PMID 24706814 DOI: 10.1073/pnas.1309438111 |
0.365 |
|
| 2014 |
Wills ES, Roepman R, Drenth JP. Polycystic liver disease: ductal plate malformation and the primary cilium. Trends in Molecular Medicine. 20: 261-70. PMID 24506938 DOI: 10.1016/j.molmed.2014.01.003 |
0.368 |
|
| 2014 |
Cnossen WR, Drenth JP. A novel twist in polycystic liver disease. Gut. 63: 1533-4. PMID 24465029 DOI: 10.1136/gutjnl-2013-306492 |
0.348 |
|
| 2014 |
Wijnands TF, Neijenhuis MK, Kievit W, Nevens F, Hogan MC, Torres VE, Gevers TJ, Drenth JP. Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume. Liver International : Official Journal of the International Association For the Study of the Liver. 34: 1578-83. PMID 24313956 DOI: 10.1111/liv.12430 |
0.308 |
|
| 2013 |
Gevers TJ, Inthout J, Caroli A, Ruggenenti P, Hogan MC, Torres VE, Nevens F, Drenth JP. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gastroenterology. 145: 357-65.e1-2. PMID 23665274 DOI: 10.1053/j.gastro.2013.04.055 |
0.327 |
|
| 2013 |
Chrispijn M, Gevers TJ, Hol JC, Monshouwer R, Dekker HM, Drenth JP. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial. Journal of Hepatology. 59: 153-9. PMID 23499726 DOI: 10.1016/j.jhep.2013.03.004 |
0.31 |
|
| 2013 |
Gevers TJ, Drenth JP. Diagnosis and management of polycystic liver disease. Nature Reviews. Gastroenterology & Hepatology. 10: 101-8. PMID 23296249 DOI: 10.1038/nrgastro.2012.254 |
0.377 |
|
| 2012 |
Gevers TJ, Chrispijn M, Wetzels JF, Drenth JP. Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease. Bmc Nephrology. 13: 17. PMID 22475206 DOI: 10.1186/1471-2369-13-17 |
0.371 |
|
| 2012 |
Zingg-Schenk A, Caduff J, Azzarello-Burri S, Bergmann C, Drenth JP, Neuhaus TJ. Boy with autosomal recessive polycystic kidney and autosomal dominant polycystic liver disease. Pediatric Nephrology (Berlin, Germany). 27: 1197-200. PMID 22415584 DOI: 10.1007/s00467-012-2137-5 |
0.345 |
|
| 2011 |
Chrispijn M, Drenth JP. Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial. Trials. 12: 246. PMID 22104015 DOI: 10.1186/1745-6215-12-246 |
0.328 |
|
| 2011 |
Janssen MJ, Waanders E, Te Morsche RH, Xing R, Dijkman HB, Woudenberg J, Drenth JP. Secondary, somatic mutations might promote cyst formation in patients with autosomal dominant polycystic liver disease. Gastroenterology. 141: 2056-2063.e2. PMID 21856269 DOI: 10.1053/j.gastro.2011.08.004 |
0.331 |
|
| 2011 |
Keimpema LV, Drenth JPH. Polycystic liver disease: A critical appraisal of hepatic resection, cyst fenestration, and liver transplantation Annals of Surgery. 253: 419. PMID 21173690 DOI: 10.1097/SLA.0b013e3182080423 |
0.329 |
|
| 2011 |
Drenth JP, Chrispijn M, Bergmann C. Congenital fibrocystic liver diseases. Best Practice & Research. Clinical Gastroenterology. 24: 573-84. PMID 20955960 DOI: 10.1016/j.bpg.2010.08.007 |
0.313 |
|
| 2011 |
Van Keimpema L, De Koning DB, Van Hoek B, Van Den Berg AP, Van Oijen MG, De Man RA, Nevens F, Drenth JP. Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver International : Official Journal of the International Association For the Study of the Liver. 31: 92-8. PMID 20408955 DOI: 10.1111/j.1478-3231.2010.02247.x |
0.331 |
|
| 2010 |
Kok KF, te Morsche RH, van Oijen MG, Drenth JP. Prevalence of genetic polymorphisms in the promoter region of the alpha-1 antitrypsin (SERPINA1) gene in chronic liver disease: a case control study. Bmc Gastroenterology. 10: 22. PMID 20170533 DOI: 10.1186/1471-230X-10-22 |
0.322 |
|
| 2010 |
Janssen MJ, Waanders E, Woudenberg J, Lefeber DJ, Drenth JP. Congenital disorders of glycosylation in hepatology: the example of polycystic liver disease. Journal of Hepatology. 52: 432-40. PMID 20138683 DOI: 10.1016/j.jhep.2009.12.011 |
0.307 |
|
| 2009 |
van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MGH, Hoffmann AL, Dekker HM, de Man RA, Drenth JPH. Lanreotide Reduces the Volume of Polycystic Liver: A Randomized, Double-Blind, Placebo-Controlled Trial Gastroenterology. 137. PMID 19646443 DOI: 10.1053/j.gastro.2009.07.052 |
0.322 |
|
| 2009 |
Waanders E, van Keimpema L, Brouwer JT, van Oijen MG, Aerts R, Sweep FC, Nevens F, Drenth JP. Carbohydrate antigen 19-9 is extremely elevated in polycystic liver disease. Liver International : Official Journal of the International Association For the Study of the Liver. 29: 1389-95. PMID 19515221 DOI: 10.1111/j.1478-3231.2009.02055.x |
0.318 |
|
| 2008 |
Waanders E, Van Krieken JH, Lameris AL, Drenth JP. Disrupted cell adhesion but not proliferation mediates cyst formation in polycystic liver disease. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 21: 1293-302. PMID 18587325 DOI: 10.1038/modpathol.2008.115 |
0.344 |
|
| 2008 |
Waanders E, Lameris AL, Op den Camp HJ, Pluk W, Gloerich J, Strijk SP, Drenth JP. Hepatocystin is not secreted in cyst fluid of hepatocystin mutant polycystic liver patients. Journal of Proteome Research. 7: 2490-5. PMID 18419150 DOI: 10.1021/pr8000282 |
0.305 |
|
| 2008 |
van Keimpema L, de Koning DB, Strijk SP, Drenth JP. Aspiration-sclerotherapy results in effective control of liver volume in patients with liver cysts. Digestive Diseases and Sciences. 53: 2251-7. PMID 18299984 DOI: 10.1007/s10620-007-0121-x |
0.303 |
|
| 2008 |
Waanders E, Croes HJ, Maass CN, te Morsche RH, van Geffen HJ, van Krieken JH, Fransen JA, Drenth JP. Cysts of PRKCSH mutated polycystic liver disease patients lack hepatocystin but express Sec63p. Histochemistry and Cell Biology. 129: 301-10. PMID 18224332 DOI: 10.1007/s00418-008-0381-3 |
0.345 |
|
| 2008 |
Hoevenaren IA, Wester R, Schrier RW, McFann K, Doctor RB, Drenth JPH, Everson GT. Polycystic liver: Clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease Liver International. 28: 264-270. PMID 17927714 DOI: 10.1111/j.1478-3231.2007.01595.x |
0.338 |
|
| 2007 |
van Keimpema L, Ruurda JP, Ernst MF, van Geffen HJ, Drenth JP. Laparoscopic fenestration of liver cysts in polycystic liver disease results in a median volume reduction of 12.5%. Journal of Gastrointestinal Surgery : Official Journal of the Society For Surgery of the Alimentary Tract. 12: 477-82. PMID 17957434 DOI: 10.1007/s11605-007-0376-8 |
0.331 |
|
| 2007 |
Berends MA, Snoek J, de Jong EM, Van Krieken JH, de Knegt RJ, van Oijen MG, van de Kerkhof PC, Drenth JP. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Liver International : Official Journal of the International Association For the Study of the Liver. 27: 639-45. PMID 17498249 DOI: 10.1111/j.1478-3231.2007.01489.x |
0.308 |
|
| 2006 |
Waanders E, te Morsche RH, de Man RA, Jansen JB, Drenth JP. Extensive mutational analysis of PRKCSH and SEC63 broadens the spectrum of polycystic liver disease. Human Mutation. 27: 830. PMID 16835903 DOI: 10.1002/humu.9441 |
0.367 |
|
| 2006 |
Peces R, Drenth JP, Te Morsche RH, González P, Peces C. Autosomal dominant polycystic liver disease in a family without polycystic kidney disease associated with a novel missense protein kinase C substrate 80K-H mutation. World Journal of Gastroenterology. 11: 7690-3. PMID 16437702 DOI: 10.3748/wjg.v11.i48.7690 |
0.359 |
|
| 2005 |
Drenth JP, Martina JA, van de Kerkhof R, Bonifacino JS, Jansen JB. Polycystic liver disease is a disorder of cotranslational protein processing. Trends in Molecular Medicine. 11: 37-42. PMID 15649821 DOI: 10.1016/J.Molmed.2004.11.004 |
0.518 |
|
| 2004 |
Drenth JP, Martina JA, Te Morsche RH, Jansen JB, Bonifacino JS. Molecular characterization of hepatocystin, the protein that is defective in autosomal dominant polycystic liver disease. Gastroenterology. 126: 1819-27. PMID 15188177 DOI: 10.1053/J.Gastro.2004.02.023 |
0.517 |
|
| 2004 |
Drenth JP, Tahvanainen E, te Morsche RH, Tahvanainen P, Kääriäinen H, Höckerstedt K, van de Kamp JM, Breuning MH, Jansen JB. Abnormal hepatocystin caused by truncating PRKCSH mutations leads to autosomal dominant polycystic liver disease. Hepatology (Baltimore, Md.). 39: 924-31. PMID 15057895 DOI: 10.1002/hep.20141 |
0.348 |
|
| 2003 |
Drenth JPH, Te Morsche RHM, Smink R, Bonifacino JS, Jansen JBMJ. Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease Nature Genetics. 33: 345-347. PMID 12577059 DOI: 10.1038/Ng1104 |
0.475 |
|
| Show low-probability matches. |